Colon And Rectal Cancer Drugs Market to Observe Prominent Growth by 2024, Trends, and Segmentation Analysis to 2031 | Amgen Inc., AstraZeneca plc, Bayer AG

Market Overview:

Colon and rectal cancer drugs are primarily used for treatment of colon cancer and rectal cancer. Colon cancer, also known as colorectal cancer, usually originates from the inner lining of the large intestine or . These cancer drugs work by slowing or stopping the growth of cancer cells. The commonly used colon and rectal cancer drugs include 5-FU, Capecitabine, Irinotecan, and Oxaliplatin.

Market Dynamics:

The growth of the global colon and rectal cancer drugs market is majorly driven by increasing incidence of colon and rectal cancer. According to the National Cancer Institute, in 2022, there will be an estimated 149,500 new cases of colon and cancer diagnosed in the United States and approximately 52,980 Americans are expected to die from the disease. Additionally, lifestyle changes such as increasing consumption of processed foods, alcohol, smoking and lack of physical activity are leading to rise in risk of colon cancer, thereby fueling the demand for colon and rectal cancer drugs. Furthermore, ongoing research and development activities for development of novel colon and rectal cancer drugs with greater efficacy is also expected to offer lucrative opportunities for market growth over the forecast period.

Request a Sample Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/2019

Top Companies Covered In This Report: Amgen Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo Company, Merck KGaA, Novartis International AG, Sirtex Medical Limited, Sanofi S.A. Sorrento Therapeutics, and Takeda Pharmaceutical Company Ltd

Market Segmentation:

By Drug Type:

Single Drug
Colon Cancer
Cetuximab
Bevacizumab
Avastin
Capecitabine
Nivolumab
Panitumumab
Oxaliplatin
Others
Rectal Cancer
Avastin
Capecitabine
Erbitux
Cyramza
Irinotecan Hydrochloride
Nivolumab
Others
Combination Drug
Colon Cancer
CAPOX
FOLFOX
FOLFIRI
FOLFIRI-CETUXIMAB
XELIRI
Others
Rectal Cancer
FU-LV
CAPOX
FOLFIRI-BEVACIZUMAB
XELOX
XELIRI
Others

By Distribution Channels:

Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies

Geographically, the detailed analysis of consumption, revenue, Colon And Rectal Cancer Drugs Market share, growth rate, etc. of the following regions:

» North America (United States, Canada, and Mexico)
» Europe (Germany, France, UK, Russia, Italy)
» Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
» Latin America (Brazil, Argentina, Colombia)
» Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Direct Buy This Premium Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2019

Major Drivers for Innovation in Colon And Rectal Cancer Drugs

Increasing Incidence of Colon and Rectal Cancers

The incidence rates of both colon and rectal cancers have been steadily increasing over the past few decades. According to statistics, colon cancer is now the third most commonly diagnosed cancer in males and the second in females worldwide. Similarly, rectal cancer accounts for over 150,000 new cases annually. With a growing aging population and changing lifestyle factors such as increasing obesity rates and lack of physical activity, the occurrences of these cancers are projected to rise further in the coming years. This growing disease burden has compelled pharmaceutical companies to focus on research and development of more effective treatment options.

Advancements in Targeted Drug Therapies

Significant progress has been made in understanding the molecular pathways involved in colon and rectal cancer development. This has enabled researchers to design targeted drugs that interfere with specific genes, proteins, and processes known to drive cancer growth and progression. Drugs such as cetuximab, panitumumab, regorafenib, and trifluridine-tipiracil have been developed to target critical pathways like Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor (VEGF). Compared to traditional chemotherapies, these targeted therapies demonstrate superior efficacy and an improved safety profile with fewer side effects. Their success has further spurred R&D of newer targeted agents against novel targets.

Major Market Restrain for Colon And Rectal Cancer Drugs

High Cost of Developing Drugs

Developing innovative cancer drugs is an extremely long, complex and capital-intensive process. It takes over 10-15 years and an estimated investment of over $2.6 billion from drug discovery to final regulatory approval. Significant funding is needed for preclinical and clinical research involving several phases of testing for efficacy, safety and side effects. Moreover, the failure rate during clinical development is quite high with only around 12% of candidate drugs ultimately getting approved. This involves major financial losses for pharmaceutical companies. The recovery of such huge costs contributes to the steep prices of new cancer drugs, restricting accessibility for some patients and health systems.

Major Market Opportunity for Colon And Rectal Cancer Drugs

Potential for Combination Therapies

While monotherapy with single targeted agents or chemotherapy has improved outcomes, promising results have been demonstrated with combination regimens. Clinical trials are exploring additive or synergistic benefits of pairing different classes of drugs that impact distinct pathways and mechanisms. For example, combining EGFR inhibitors with VEGF blockers aims to maximize anti-angiogenic and anti-tumor effects. Combining immunotherapies like checkpoint inhibitors with conventional or targeted therapies may help activate immune response against cancer cells. Successful combination approaches can offer superior clinical benefits to patients, driving demand. This represents a major opportunity area for drug developers.

Emerging Market Trend in Colon And Rectal Cancer Drugs

Rise of Precision Medicine and Immunotherapies

Growing understanding of tumor genetics and immunology is fueling major trends in colon and rectal cancer treatment. Precision or personalized medicine aims to match therapies to specific abnormalities in a patient's cancer. For instance, drugs targeting rare genomic mutations like BRAF-V600E that define a subset of tumors. Immunotherapies harness the immune system to fight cancers and have shown promise. Checkpoint inhibitors releasing brakes on immune T-cells have been approved. Continued research in combining immunotherapies with targeted drugs or chemotherapy aims to maximize immune-stimulatory effects. These cutting-edge approaches are anticipated to transform colon and rectal cancer management outcomes through customized, individualized treatment strategies.

Reason to Buy Our Market Research Report:

- Enhance your decision-making capability in a more rapid and time-sensitive manner.
- Identify key growth and investment opportunities in the Thrombolytic Therapy market.
- Facilitate decision-making based on strong historic and forecast data for the Thrombolytic Therapy market.
- Position yourself to gain the maximum advantage of the industry's growth potential.
- Identify key partners and business development avenues.
- Understand and respond to your competitors' business structure, strategy, and prospects

𝐅𝐀𝐐'𝐬

Q.1 What are the main factors influencing the Colon And Rectal Cancer Drugs market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market's opportunities, risks, and general structure?
Q.4 Which of the top Colon And Rectal Cancer Drugs Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Colon And Rectal Cancer Drugs market's distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area's assessment of agreements, income, and value implicate?

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/2019

Contact Us:

Mr. Shah
Coherent Market Insights Pvt. Ltd,
📞Phone: U.S.: +1-206-701-6702
📞U.K.: +44-020-8133-4027
📞JAPAN: +81-50-5539-1737
📞INDIA: +91-848-285-0837
✉ Email: sales@coherentmarketinsights.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.